Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated)

Pharmacotherapy

Volumn 22, Issue 12 II, 2002, Pages

  Rudis, Maria I ^b   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b PSC 700   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CYTOKINE; D DIMER; DROTRECOGIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; THROMBIN; THROMBOMODULIN;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; BABOON; BLEEDING; BLOOD CLOTTING; BODY WEIGHT; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; CONTINUOUS INFUSION; DEHYDRATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; FIBRIN FORMATION; FIBRINOLYSIS; GENE TRANSLOCATION; HEMODIALYSIS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; MACROPHAGE; MICROCIRCULATION; MONOCYTE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OLIGURIA; PARTIAL THROMBOPLASTIN TIME; PERITONEAL DIALYSIS; PLASMA CLEARANCE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

EID: 0036896688     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.18.182s.33704     Document Type: Review

References (41)

1. Esmon CT, Taylor FB Jr, Snow TR. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991;66:160-5.
2. Yan SB, Grinnell BW. Recombinant human protein C, protein S, and thrombomodulin as antithrombotics. Perspect Drug Discovery Res 1993;1:503-20.
3. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738-42.
4. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988;72:128-33.
5. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83:4533-7.
6. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135-45.
7. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6.
8. Esmon CT, Xu J, Gu JM, et al. Endothelial protein C receptor. Thromb Haemost 1999;82:251-8.
9. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;29(suppl 7):S48-51.
10. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991;115:223-34.
11. Jackson CVST, Bailey BD, Gerlitz BE, Berg BE, Grinnell BW. Recombinant human activated protein C (LY203638)-induced reperfusion in a canine model of occlusive coronary artery thrombosis [abstr]. Circulation 1998;98(suppl 1):1454.
12. Grinnell BW, Yan SB. Novel antithrombotics based on modulation of the protein C pathway. Coron Artery Dis 1998;9:89-97.
13. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-6.
14. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000;83:639-43.
15. Schmidt-Supprian M, Murphy C, While B, et al. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur Cytokine Netw 2000;11:407-13.
16. Stefanec T. Endothelial apoptosis: Could it have a role in the pathogenesis and treatment of disease? Chest 2000;117:841-54.
17. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000;28(suppl 4):N105-13.
18. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429-42.
19. White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κ B (NF-κ B) and tumour necrosis factor α (TNF-α) production in the THP-1 monocytic cell line. Br J Haematol 2000;110:130-4.
20. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.
21. Taylor F, Chang A, Ferrell G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-63.
22. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000;95:1680-6.
23. Hancock WW, Tsuchida A, Hau H, Thomson NM, Salem HH. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc 1992;24:2302-3.
24. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001;97:1685-8.
25. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29(suppl 7):S69-74.
26. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.
27. U.S. Food and Drug Administration. Briefing Document for Xigris for the Treatment of Severe Sepsis. Anti-Infective Drugs Advisory Committee meetings page. Available from www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_01_ Sponsor.pdf. Accessed July 12, 2002.
28. Howey DC, Hartman DL. Preparation for trials of recombinant human activated protein C in sepsis: A pharmacokinetic and dynamic study in healthy men and women [abstr]. Chest 1997;112:S89.
29. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9.
30. Bernard GR, Vincent JL, Laterre PF, et al, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
31. U.S. Food and Drug Administration. Product Approval Information. Center for Biologics Evaluation and Research page. Available from www.fda.gov/cber/approvltr/droteli 112101L.htm. Accessed July 12, 2002.
32. Anonymous. Activated protein C (Xigris) for severe sepsis. Med Lett Drugs Ther 2002;44:17-18.
33. Kanji S, Devlin JW, Piekos KA, Racine E. Recombinant human activated protein C, drotrecogin alfa (activated): A novel therapy for severe sepsis. Pharmacotherapy 2001;21:1389-402.
34. Bernard G. Satellite symposia. Presented at the Society of Critical Care Medicine 31st Critical Care Congress, San Diego, January 20-30, 2002.
35. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000;28(suppl 9):S9-11.
36. Schilske HK. FDA Anti-Infective Drugs Advisory Committee 10/16/01 Slides. Lilly, Inc. Available at www.fda.gov/ohrms/ dockets/ac/01/slides/3797s1.htm. Accessed July 12, 2002.
37. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
38. Fitch SJ, Gossage JR. Optimal management of septic shock: Rapid recognition and institution of therapy are crucial. Postgrad Med 2002;111:53-6, 59-60, 63-4 passim.
39. Bastian L, Weimann A. Immunonutrition in patients after multiple trauma. Br J Nutr 2002;87(suppl 1):S133-4.
40. Bastian L, Weimann A, Bischoff W, et al. Clinical effects of supplemental enteral nutrition solution in severe polytrauma [in German]. Unfallchirurg 1998;101:105-14.
41. Angus D. Satellite symposia. Presented at the Society of Critical Care Medicine 31st Critical Care Congress, San Diego, January 20-30, 2002.